Boundless Bio Files S-4 for Reverse Merger with Serapha Bio: 96.2% Dilution, $44-48M Dividend, and Beam Litigation Risk

summarizeSummary

Boundless Bio's S-4 reveals the full terms of its reverse merger with Serapha Bio: existing stockholders keep only 3.8% of the combined company but receive a $44-48M cash dividend, while Serapha brings a Phase 1 gene therapy for AATD and $230M in committed financing. The deal is contingent on a reverse stock split and faces litigation risk from Beam Therapeutics.

check_boxKey Events · M&A and Partnerships · BOLD

• Reverse Merger Terms Finalized

  Exchange ratio of 8.6737 Boundless Bio shares per Serapha share. Existing Boundless Bio stockholders will own approximately 3.8% of the combined company on a fully-diluted basis; Serapha securityholders and pre-closing financing investors will own approximately 96.2%.

• Pre-Closing Dividend of $44-48M

  Boundless Bio stockholders of record will receive a special cash dividend of approximately $44 million to $48 million — substantially all of the company's remaining net cash — prior to the merger closing.

• Serapha Financing Totals $230M

  Serapha completed a $138 million Series A preferred stock financing and has commitments for a $92 million pre-closing financing at $4.4997 per share. The pre-closing financing is a condition to closing the merger.

• Beam Litigation Threatens SERP-01

  Beam Therapeutics filed suit on September 25, 2026 alleging trade secret misappropriation against Serapha, YolTech, and two individuals related to SERP-01, Serapha's only product candidate. An adverse outcome could prevent development or commercialization of SERP-01.

auto_awesomeAnalysis · BOLD · Life Sciences

This S-4 registration statement is the definitive disclosure of the reverse merger between Boundless Bio and Serapha Bio. Existing Boundless Bio stockholders will be diluted to approximately 3.8% ownership of the combined company, while Serapha securityholders and pre-closing financing investors will own approximately 96.2%. In exchange, Boundless Bio stockholders receive a pre-closing dividend of approximately $44-48 million — essentially all of the company's remaining net cash. The deal is a survival transaction: Boundless Bio has halted all R&D, cut 75% of staff, and faces liquidation if the merger fails. The newly disclosed Beam Litigation (filed September 25, 2026) alleging trade secret misappropriation against Serapha and its licensor YolTech adds significant risk to the combined company's only product candidate, SERP-01. The merger requires a reverse stock split to meet Nasdaq's $4.00 minimum listing price, and the combined company will trade under the symbol 'AATD' if approved.